Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 23;11:17027. doi: 10.1038/s41598-021-96418-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Liraglutide, dosed once daily at 25 nmol/kg IP does not slow disease progression in a TDP-43^Q331K transgenic mouse model of ALS. (A) Daily average body weight (mean ± SD) of mice dosed with vehicle or liraglutide, once daily, ip from 25 days to 6 months of age. As expected, TDP-43^Q331K mice gain weight through to 6 months of age. No significant difference was seen in bodyweight data between the two groups (n = 14 per group, two-way ANOVA with repeated measures P = 0.7442). Average shown by thick line, ± SD shown by thin dashed lines (B) Rotarod data shown as average latency to fall (mean ± SD) from 50 to 180 days of age. Performance on rotarod declined over time as expected from the model but there was no significant difference between the two dose groups (n = 14 per group, two-way ANOVA with repeated measures P = 0.5741). (C) Compound muscle action potential (CMAP) amplitude at 6 weeks, 3 months and 6 months of age shown as individual values with mean ± SD. There is no significant difference in CMAP between groups (n = 14 per group, two-way ANOVA with repeated measures P = 0.5655). (D) Hindlimb base of support (mean ± SD) at 3 and 6 months of age from gait analysis shows no significant difference between dose groups (n = 7 per group, two-way ANOVA P = 0.8974 NS). (E) Percentage of time spent on diagonal walking (mean ± SD) at 3 and 6 months of age (n = 7 per group, two-way ANOVA P = 0.5215 NS). (F) Percentage of time spent on four paws (mean ± SD) at 3 and 6 months of age (n = 7 per group, two-way ANOVA P = 0.3100 NS).